UNSPSC 41142029: Ornithine carbamyl transferase test system

In this classification, Ornithine carbamyl transferase test system connotes a device used to measure Ornithine carbamyl transferase levels. US FDA regulates Ornithine carbamyl transferase test system under 21 CFR 862.1535 and under FDA product code JMY.

UNSPSC 41142029 Ornithine carbamyl transferase test system is a Commodity code under which state and local governments procure laboratory diagnostic kits and reference materials for forensic drug analysis, substance screening, and public health testing operations. Recent solicitations show the code capturing purchases of direct ELISA testing kits for drug screening (cannabinoids, opiates, PCP, amphetamines, and related compounds), certified reference drug standards for analytical method validation and toxicology work, DNA screening kits for forensic laboratory analysis, and mosquito-borne illness test kits (West Nile Virus and Dengue). The issuing bodies include state law-enforcement crime labs (Texas Department of Public Safety), state health and human services agencies (Texas Health and Human Services Commission on behalf of the Department of State Health Services), county forensic laboratories (Pinellas County, Florida, in partnership with the Florida Department of Law Enforcement), and state environmental and public health departments (Illinois Department of Financial and Professional Regulation). Procurement notices span IFB, ITQ, and sole-source award processes, with many incorporating federal funding streams (Paul Coverdell Forensic Sciences Improvement Act Program) and state set-aside preferences for small and minority-owned businesses.

Recent activity concentrates in Texas and Florida, with supporting notices in Illinois. Representative opportunities include the Texas Department of Public Safety IFB 405-26R0008445A (posted July 9, 2026; due July 23, 2026) requesting direct ELISA testing kits across 12 substance categories for the Crime Lab Division in Austin; Pinellas County's Invitation to Quote #26-0305-ITQ (posted and due April 23, 2026) for 131 line items of certified reference drug standards at approximately $49,034 in federal funding; the Texas Health and Human Services Commission's IFB HHS0016902v2 (due January 29, 2026) for QIAxcel and QIAamp DNA screening kits with historical volume guidance of $25,050–$30,000 annually; and the Illinois Department of Financial and Professional Regulation's sole-source notice (May 4, 2026) for RAMP mosquito testing equipment and West Nile Virus and Dengue test kits through ADAPCO, LLC. Contracts typically run one to twelve months with optional renewal terms, include firm pricing requirements, and often require vendors to demonstrate financial solvency, past performance ratings, and compliance with HUB subcontracting plans or SBE preferences.